KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Royalty Pharma (RPRX) over the last 7 years, with Q3 2025 value amounting to -$259.3 million.

  • Royalty Pharma's Free Cash Flow rose 4719.33% to -$259.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $944.7 million, marking a year-over-year increase of 54472.28%. This contributed to the annual value of $263.3 million for FY2024, which is 6981.65% down from last year.
  • Royalty Pharma's Free Cash Flow amounted to -$259.3 million in Q3 2025, which was up 4719.33% from $362.9 million recorded in Q2 2025.
  • Over the past 5 years, Royalty Pharma's Free Cash Flow peaked at $595.0 million during Q1 2025, and registered a low of -$866.3 million during Q3 2021.
  • In the last 5 years, Royalty Pharma's Free Cash Flow had a median value of $318.2 million in 2021 and averaged $108.6 million.
  • In the last 5 years, Royalty Pharma's Free Cash Flow skyrocketed by 246727.37% in 2021 and then tumbled by 50114.8% in 2024.
  • Royalty Pharma's Free Cash Flow (Quarter) stood at $318.2 million in 2021, then rose by 0.46% to $319.7 million in 2022, then crashed by 171.82% to -$229.6 million in 2023, then soared by 207.18% to $246.1 million in 2024, then crashed by 205.34% to -$259.3 million in 2025.
  • Its Free Cash Flow was -$259.3 million in Q3 2025, compared to $362.9 million in Q2 2025 and $595.0 million in Q1 2025.